| Literature DB >> 29254482 |
Simon Greulich1,2, Philipp Kaesemann3, Andreas Seitz3, Stefan Birkmeier4, Eed Abu-Zaid3, Francesco Vecchio3, Udo Sechtem3, Heiko Mahrholdt3.
Abstract
BACKGROUND: Adenosine stress cardiovascular magnetic resonance (CMR) can detect significant coronary artery stenoses with high diagnostic accuracy. Caffeine is a nonselective competitive inhibitor of adenosine2A-receptors, which might hamper the vasodilator effect of adenosine stress, potentially yielding false-negative results. Much controversy exists about the influence of caffeine on adenosine myocardial perfusion imaging. Our study sought to investigate the effects of caffeine on ischemia detection in patients with suspected or known coronary artery disease (CAD) undergoing adenosine stress CMR.Entities:
Keywords: Adenosine; CMR; Caffeine; Ischemia; Stress
Mesh:
Substances:
Year: 2017 PMID: 29254482 PMCID: PMC5735931 DOI: 10.1186/s12968-017-0412-0
Source DB: PubMed Journal: J Cardiovasc Magn Reson ISSN: 1097-6647 Impact factor: 5.364
Fig. 1Flow chart demonstrating the study population
Patient baseline characteristics
|
| ||
|---|---|---|
| Age [yrs] | 68 ± 8 | |
| Gender | Male | 25 (83%) |
| Cardiovascular risk factors | Hypertension | 24 (80%) |
| Family history for CVD | 15 (50%) | |
| Hyperlipidemia | 25 (83%) | |
| Diabetes mellitus | 10 (33%) | |
| Smoking | 2 (6.7%) | |
| Symptoms | None | 3 (10%) |
| Angina pectoris (AP) | 16 (53.3%) | |
| Typical AP | 13 | |
| CCS I | – | |
| CCS II | 8 | |
| CCS III | 5 | |
| CCS IV | 3 | |
| Atypical AP | 3 | |
| Dyspnea | 6 (20%) | |
| NYHA I | 1 | |
| NYHA II | 4 | |
| NYHA III | 1 | |
| NYHA IV | – | |
| Typ. AP + Dyspnea | 5 (16.7%) | |
| Medication | ASS | 13 (43.3%) |
| DAPT | 7 (23.3%) | |
| ACE/ARB-Inhibitor | 13 (43.3%) | |
| Betablockers | 13 (43.3%) | |
| Statins | 17 (56.7%) | |
| Nitrates/CCB | 13 (43.3%) | |
| OAD | 6 (20%) | |
| ECG abnormalities | 20 (66.7%) | |
| Known CAD | 14 (46.7%) | |
| Prior CABG | 4 (13.3%) | |
| Prior MI/Myocardial scar | 9 (30%) | |
| Caffeine levels [mg/L] | baseline CMR | < 1 |
| follow-up CMR | 4.6 ± 2.2 | |
| Daily caffeine consumption [cups] | coffee | 3.0 ± 1.9 |
| tea | 3.0 ± 1.5 | |
| Time between baseline and follow-up CMR [days] | 13.9 | |
| CMR findings | ||
| LV-EF [%] | 62.7 ± 8.4 | |
| LV-EDV [ml] | 132.3 ± 33.2 | |
| LV-ESV [ml] | 51.6 ± 24.0 | |
| LA [cm2] | 21.6 ± 4.0 | |
| IVS [mm] | 12.6 ± 2.4 |
All values are n (%), or mean ± SD, CVD cardiovascular disease, ECG electrocardiogram, AP angina pectoris, ASS acetylsalicylic acid, DAPT dual antiplatelet therapy, ACE angiotensin converting enzyme, ARB angiotensin receptor blockers, CCB calcium channel blocker, OAD oral antidiabetic drugs, CAD coronary artery disease, CABG coronary artery bypass graft, MI myocardial infarction, CMR cardiovascular magnetic resonance, LV-EF left-ventricular ejection fraction, LV-EDV left-ventricular end-diastolic volume, LV-ESV left ventricular end-systolic volume, LA left atrium, IVS interventricular septum
Fig. 2CMR Perfusion without vs. with caffeine. Adenosine stress cardiovascular magnetic resonance (CMR) images (basal, mid-ventricular and apical slices) without intake of caffeine (a) and the corresponding images after intake of 200 mg caffeine 1 h prior a repeat adenosine stress CMR (b) of a 85-year old male with known coronary artery disease (CAD) and typical angina pectoris demonstrating a perfusion defect in septal, inferoseptal and inferior segments (9 out of 16 segments) which seems to be larger without caffeine (a) than after intake of caffeine (b). LGE images revealed no late gadolinium enhancement (LGE) (c). Coronary angiography demonstrated severe stenosis of a) the proximal part of the left anterior descending coronary artery and b) of the mid segment of the right coronary artery, matching the results of (both) adenosine CMR stress perfusions
Hemodynamic variables and symptoms
| W/o caffeine | W caffeine |
| |||
|---|---|---|---|---|---|
| Rest | Adenosine | Rest | Adenosine | ||
| Heart rate [1/min] | 66.9 ± 9.4 | 84.7 ± 11.4 | 71.3 ± 11.3 | 83.7 ± 8.1 | rest: |
| adenosine: | |||||
| Systolic blood pressure [mmHg] | 154 ± 23 | 148 ± 22 | 154 ± 25 | 152 ± 24 | rest: |
| adenosine: | |||||
| Diastolic blood pressure [mmHg] | 89 ± 13 | 88 ± 12 | 88 ± 9 | 87 ± 9 | rest: |
| adenosine: | |||||
| Symptoms of adenosine: | |||||
| Dyspnea | 47% | 43% |
| ||
| Chest pain | 28% | 31% |
| ||
Fig. 3Ischemic burden on a segment model basis. Bulls-eye graphs representing the mean signal intensity in the same patient as in fig. 2 according to a 16-segment model (a) and a 60-segment model (b) in arbitrary units, with darker colors representing lower signal intensity values indicating impaired myocardial perfusion. Top row: Caffeine-naïve adenosine stress perfusion demonstrating a larger extent of ischemic burden compared to the adenosine stress CMR after intake of caffeine in the same patient, bottom row
Fig. 4Absolute ischemic burden quantification. On the top row (a) absolute ischemic burden (in ml) is displayed without prior intake caffeine in the same patient than in Figs. 2 and 3. Bottom row (b) shows the corresponding perfusion slices after consumption of 200 mg caffeine one hour prior to the repeat scan. Similar to figs. 2 and 3, myocardial ischemic burden is reduced but still detectable in perfusion slices despite the influence of caffeine
Subgroup analysis
| N | 16-segments model | 60-segments model | Ischemic volume [ml] | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| W/o caffeine | W caffeine |
| W/o caffeine | W caffeine |
| W/o caffeine | W caffeine |
| ||
| No infarction | 21 | 7.1 ± 3.5 | 6.1 ± 3.3 | p = 0.89 | 15.8 ± 7 | 13.4 ± 7.1 | p = 0.46 | 4.1 ± 2.2 | 3.5 ± 2.4 |
|
| Infarctiona | 9 | 9.8 ± 2.9 | 8.9 ± 3.3 | 25.1 ± 9.1 | 21 ± 10.1 | 4.4 ± 3.1 | 3.2 ± 2.5 | |||
| No CAD | 14 | 8.3 ± 2.8 | 7.6 ± 3.8 |
| 20.6 ± 9.5 | 17.3 ± 10.0 |
| 4.4 ± 2.8 | 3.6 ± 3.0 |
|
| Known CAD | 16 | 7.5 ± 4.3 | 6.3 ± 3 | 16.4 ± 7.4 | 13.9 ± 6.8 | 4.0 ± 2.1 | 3.1 ± 1.4 | |||
| No CABG | 26 | 7.5 ± 3.5 | 6.6 ± 3.6 |
| 18.2 ± 9.3 | 14.8 ± 8.7 |
| 4.2 ± 2.7 | 3.3 ± 2.5 |
|
| CABG | 4 | 10.8 ± 2.2 | 9.3 ± 1 | 21.0 ± 2.9 | 21.8 ± 5.9 | 4.2 ± 0.2 | 4.3 ± 1.1 | |||
*= p-values for difference in segments/volume (w/o caffeine - w caffeine) between groups (e.g. no infarction vs. infarction)
a = defined as ischemic type late gadolinium enhancement (LGE), other abbreviations see Table 1